10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-TNFRSF7 / CD27 Reference Antibody (Organon patent anti-CD27)

Recombinant Antibody
Catalog # APR11057

Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	P26842
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG2SA
Calculated MW	29137

Additional Information

Target/Specificity	TNFRSF7 / CD27
Endotoxin Conjugation	Unconjugated
Expression system	CHO Cell
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Protein Information

Name	CD27 (HGNC:11922)
Function	Costimulatory immune-checkpoint receptor expressed at the surface of T-cells, NK-cells and B-cells which binds to and is activated by its ligand CD70/CD27L expressed by B-cells (PubMed:28011863). The CD70-CD27 signaling pathway mediates antigen- specific T-cell activation and expansion which in turn provides immune surveillance of B-cells (PubMed:28011863). Mechanistically, CD70 ligation activates the TRAF2-PTPN6 axis that subsequently inhibits LCK phosphorylation to promote phenotypic and transcriptional adaptations of T-cell memory (PubMed:38354704). In addition, activation by CD70 on early progenitor cells provides a negative feedback signal to leukocyte differentiation during immune activation and thus modulates hematopoiesis (By similarity). Negatively regulates the function of Th2 lymphocytes in the adipose tissue (By similarity).
Cellular Location	Cell membrane; Single-pass type I membrane protein
Tissue Location	Found in most T-lymphocytes.

Images



Anti-TNFRSF7 / CD27 Reference Antibody (Organon patent anti-CD27) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-TNFRSF7 / CD27 Reference Antibody (Organon patent anti-CD27)is more than 95% ,determined by SEC-HPLC.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.